



Inventors

George Robert Pettit

Regents Professor
Department of Chemistry
and Biochemistry
Arizona State University

Noeleen Melody

Assistant Research Professor
Department of Chemistry
and Biochemistry
Arizona State University

Intellectual Property

Status:

U.S. Patents 7,351,830
7,541,346

Contact

Thomas Goodman, PhD

Director

Business Development, Life
Sciences

Arizona Technology
Enterprises, LLC (AzTE)

P: 480.884.1648

F: 480.884.1984

TOMGOODMAN@AZTE.COM

HEALTHSCIENCES@AZTE.COM

Pancreatistatin Cyclic Phosphate Prodrugs and Phenpanstatin Cyclic Phosphate Prodrugs

AzTE Case # M02-054

Invention Description

The early promise of pancreatistatin as a new type of anticancer and antiviral drug led to various preclinical developments. While there have been improvements to the availability of pancreatistatin by the development of new horticultural and synthetic approaches, still there is a need for more efficient techniques for the conversion of pancreatistatin to the water soluble phosphate prodrug.

Researchers at Arizona State University have developed a new series of promising 3, 4-O cyclic phenpanstatin phosphate prodrugs, 3,4-O cyclic pancreatistatin phosphate prodrugs, and 4-O sodium pancreatistatin phosphate drugs. They have also developed novel methods for synthesizing each of these new compounds.

The prodrugs exhibit excellent cancer cell inhibitory activity. This suggests that they could be developed into significant anticancer drugs. Pancreatistatin has also been found to display remarkable activity against microspirochosis, another potentially lethal challenge for some cancer patients.

Potential Applications

- Phosphate prodrugs
- Anticancer drugs
- Antiviral drugs

Benefits and Advantages

- Can be prepared as a capsule or for injection
- Oral administration could be either solid or liquid